These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 21506647)

  • 1. CpG DNA as a vaccine adjuvant.
    Bode C; Zhao G; Steinhagen F; Kinjo T; Klinman DM
    Expert Rev Vaccines; 2011 Apr; 10(4):499-511. PubMed ID: 21506647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
    Klinman DM; Klaschik S; Sato T; Tross D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of CpG oligodeoxynucleotides as immune adjuvants.
    Klinman DM; Currie D; Gursel I; Verthelyi D
    Immunol Rev; 2004 Jun; 199():201-16. PubMed ID: 15233736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.
    Scheiermann J; Klinman DM
    Vaccine; 2014 Nov; 32(48):6377-89. PubMed ID: 24975812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
    Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
    Front Immunol; 2018; 9():783. PubMed ID: 29720976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant activity of CpG oligodeoxynucleotides.
    Klinman DM
    Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies.
    Hanagata N
    Int J Nanomedicine; 2017; 12():515-531. PubMed ID: 28144136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG DNA as a vaccine adjuvant.
    Klinman DM
    Expert Rev Vaccines; 2003 Apr; 2(2):305-15. PubMed ID: 12899580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
    Jin JW; Tang SQ; Rong MZ; Zhang MQ
    Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG oligodeoxynucleotides as mucosal adjuvants.
    Iho S; Maeyama J; Suzuki F
    Hum Vaccin Immunother; 2015; 11(3):755-60. PubMed ID: 25751765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Crit Rev Immunol; 2001; 21(1-3):103-20. PubMed ID: 11642598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PyNTTTTGT prototype oligonucleotide IMT504, a novel effective adjuvant of the FMDV DNA vaccine.
    Zhao G; Jin H; Li J; Su B; Du X; Kang Y; Wang X; Wang B
    Viral Immunol; 2009 Apr; 22(2):131-8. PubMed ID: 19327000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmanial CpG DNA nanovesicles: A propitious prophylactic approach against visceral leishmaniasis.
    Tiwari RK; Chandrakar P; Gupta CL; Sayyed U; Shekh R; Bajpai P
    Int Immunopharmacol; 2021 Jan; 90():107181. PubMed ID: 33249044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytosine-phosphate-guanine oligodeoxynucleotides containing GACGTT motifs enhance the immune responses elicited by keyhole limpet hemocyanin antigen in dairy cattle.
    Chu CY; Lee SC; Liu SS; Lin YM; Shen PC; Yu C; Lee KH; Zhao X; Lee JW
    Nucleic Acid Ther; 2011 Oct; 21(5):323-32. PubMed ID: 21916610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG oligodeoxynucleotides as vaccine adjuvants in primates.
    Verthelyi D; Kenney RT; Seder RA; Gam AA; Friedag B; Klinman DM
    J Immunol; 2002 Feb; 168(4):1659-63. PubMed ID: 11823494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies.
    Karbach J; Neumann A; Wahle C; Brand K; Gnjatic S; Jäger E
    Cancer Res; 2012 Sep; 72(17):4304-10. PubMed ID: 22738916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of CpG oligodeoxynucleotides in veterinary species.
    Ioannou XP; Griebel P; Mena A; Gomis SM; Godson DL; Mutwiri G; Hecker R; Babiuk LA; van Drunen Littel-van den Hurk S
    Antisense Nucleic Acid Drug Dev; 2003; 13(3):157-67. PubMed ID: 12954116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.
    Becker Y
    Virus Genes; 2005 Mar; 30(2):251-66. PubMed ID: 15744581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.